SEC Tracker
Get the app

AVROBIO TECX

AVROBIO: announces exit or restructuring costs and reports an executive or board change

Form
8-K
Filed
Period
Importance
Major
Document
8-K
  • Announces exit or restructuring costs (2.05)
  • Reports an executive or board change (5.02)

Not explained yet; the original is on EDGAR.

View on EDGAR

Open in the app

Get an email when AVROBIO files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Same SIC code (2836) and public float under $300M, nearest public float first, as each company reports it on its annual report cover.

  1. Replimune Group REPL public float $235M, Sep 30, 2025
  2. Prime Medicine PRME public float $239M, Jun 30, 2025
  3. Liminatus Pharma LIMN public float $221M, Jun 30, 2025
  4. Candel Therapeutics CADL public float $245M, Jun 30, 2025
  5. Lexeo Therapeutics LXEO public float $217M, Jun 30, 2025

Data on this page was fetched . The filing on SEC.gov is the record.